Viatris (VTRS) Net Cash Flow (2019 - 2026)
Viatris (VTRS) posted Net Cash Flow of -$912.4 million for Q2 2026, down 297.53% on a QoQ basis from $461.9 million in Q1 2026, and down 367.42% year-over-year from $341.2 million in Q2 2025.
Analysis
Viatris (VTRS) Net Cash Flow (2019 - 2026) Analysis & Trends
Viatris has reported Net Cash Flow for 8 years, with the latest figure at -$912.4 million in Q2 2026.
- On a quarterly basis, Net Cash Flow fell 367.42% year-over-year to -$912.4 million in Q2 2026; TTM through Jun 2026 was $335.6 million, a 193.14% increase from a year earlier, with the FY2025 full-year figure at $594.3 million, up 362.04% from the prior year.
- Net Cash Flow was -$912.4 million for Q2 2026 at Viatris, down from $461.9 million in the prior quarter.
- The five-year high for Net Cash Flow was $937.7 million in Q3 2024, with the low at -$1.1 billion in Q4 2024.
- Average Net Cash Flow over 5 years is $13.7 million, with a median of $19.0 million recorded in 2024.
- The largest YoY upside for Net Cash Flow was 14625.53% in 2023 against a maximum downside of 1302.88% in 2023.
- Over 5 years, Net Cash Flow stood at $596.5 million in 2022, then plunged by 155.47% to -$330.9 million in 2023, then sank by 234.3% to -$1.1 billion in 2024, then soared by 133.29% to $368.2 million in 2025, then slumped by 347.8% to -$912.4 million in 2026.
- The last three Net Cash Flow figures came in at -$912.4 million (Q2 2026), $461.9 million (Q1 2026), and $368.2 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -81.00 Mn |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -912.40 Mn |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -44.45 Mn |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -64.63 Mn |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 528.00 Mn |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | 78.82 Mn |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | 48.97 Mn |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 52.66 Mn |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -912.40 Mn |
| Mar 31, 2026 | 461.90 Mn |
| Dec 31, 2025 | 368.20 Mn |
| Sep 30, 2025 | 417.90 Mn |
| Jun 30, 2025 | -195.20 Mn |
| Mar 31, 2025 | 3.40 Mn |
| Dec 31, 2024 | -1.11 Bn |
| Sep 30, 2024 | 937.70 Mn |
| Jun 30, 2024 | -93.00 Mn |
| Mar 31, 2024 | 34.70 Mn |
| Dec 31, 2023 | -330.90 Mn |
| Sep 30, 2023 | 682.70 Mn |
| Jun 30, 2023 | 134.80 Mn |
| Mar 31, 2023 | -753.00 Mn |
| Dec 31, 2022 | 596.50 Mn |
| Sep 30, 2022 | -4.70 Mn |
| Jun 30, 2022 | -59.20 Mn |
| Mar 31, 2022 | 62.60 Mn |
| Dec 31, 2021 | -45.20 Mn |
| Sep 30, 2021 | 89.90 Mn |